Table 1.
n (%) | |
---|---|
Age at diagnosis (years) | |
Mean | 56.6 |
Standard deviation | 13.1 |
Gender | |
Male | 6 (54.5) |
Female | 5 (45.5) |
Site of disease | |
Stomach | 3 (27.2) |
Colorectum | 3 (27.2) |
Pancreas | 5 (45.6) |
Histological classification | |
G3 NET | 6 (54.5) |
G3 NEC | 5 (45.5) |
FDG-PET/CT | |
Positive | 8 (72.7) |
Not done | 3 (27.3) |
68Ga-PET/CT octreoscan | |
Positive | 4 (36.4) |
Negative | 6 (54.5) |
Not done | 1 (9.1) |
Chemotherapy | |
CDDP | 8 (72.7) |
Carboplatin | 2 (18.1) |
Other | 1 (9.2) |
Best response to first-line chemotherapy | |
PD | 3 (27.2) |
SD | 3 (27.2) |
PR | 5 (45.6) |
Median overall survival, months [range] | 23 [6-70] |
NEC: neuroendocrine carcinoma; NET: neuroendocrine tumor; G: grade; FDG-PET/CT: fluorodeoxyglucose-positron emission tomography/computerized tomography; 68Ga: Gallium-68; CDDP: cisplatin; PD: progressive disease; SD: stable disease; PR: partial response.